Uncategorized-EN

In close collaboration with experts, patients and the SPAGN board, SPAGN identifies specific topics and brings the key players together to discuss and form a common statement or publication to address the topic and spread knowledge. Recent roundtables were: TGCT Consensus Initiative June 21, 2022, Frankfurt. Global consensus paper has been submitted.   CTOS-SPAEN Initiative…

Advocacy in Action Award 2025 Winners Patient advocacy continues to be a powerful force for progress—amplifying voices, breaking down barriers, and sparking meaningful change. In the world of sarcoma, advocacy plays a key role in driving awareness, improving care, and supporting those impacted by this rare group of cancers. For 2025, we are once again…

Change can only happen if all stakeholders are working together. That’s why SPAEN is also active in EU-funded and international projects: STREXIT2 SELNET The SELNET project (SELNET has received funding from the European Union’s Horizon 2020 research and innovation programme) seeks to create a European and Latin American multidisciplinary network of clinical and translational specialists…

Since GIST hardly produce any symptoms, they are often quite large before they are discovered. Those tumors are often discovered during emergency surgery for unexpected perforation of the gastrointestinal tract and consequent bleeding.The type of symptoms and when they first occur depends on the size and location of the tumor. If the tumor is situated…

GISTs are malignant tumours of soft tissues in the gastro-intestinal tract (the stomach and intestines). They are classed as sarcomas, which account for approximately 1% of all cancer diagnoses. Sarcomas originate from cells in connective tissues, bones, muscles, fat, nerves, blood vessels, and cartilage. Most commonly, primary GISTs develop in the stomach (50-70 %), followed…